Q4 2024 PDS Biotechnology Corp Earnings Call Transcript
Key Points
- PDS Biotechnology Corp (PDSB) initiated the VERSATILE-003 phase 3 clinical trial for HPV16 positive head and neck cancer, which is a significant step forward in their clinical development program.
- The VERSATILE-002 phase 2 study showed promising results with a median overall survival of 30 months, significantly higher than the 17.9 months for Pembrolizumab alone.
- The company received FDA clearance for their investigational new drug application for a combination therapy targeting metastatic colorectal cancer, expanding their pipeline.
- PDS Biotechnology Corp (PDSB) has a strong relationship with the National Cancer Institute, which supports their research and development efforts.
- The company successfully raised $11 million in a direct offering, providing additional funding to support ongoing clinical trials.
- PDS Biotechnology Corp (PDSB) reported a net loss of $37.6 million for the year ended December 31, 2024, indicating ongoing financial challenges.
- The company does not currently have enough funds to complete the VERSATILE-003 trial and will need to raise additional capital.
- There are uncertainties regarding the enrollment rates and timelines for the VERSATILE-003 trial, which could impact the trial's progress.
- The funding environment is challenging, and the company may need to explore various options, including debt, to secure necessary capital.
- The TARP program for prostate cancer is not currently prioritized, with no specific timelines provided for its progression.
Good morning and welcome to PDS Biotech's fourth quarter in full year 2024 earnings conference call.
(Operator Instructions)
Tom Johnson, LifeSci Advisors, LLC.
Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's 2024 results and clinical program update call. I'm joined in the calls today by the following members of the company's management team Dr. Frank Bedu Addo, Chief Executive Officer, Dr. Kirk Shepard, Chief Medical Officer, and Lars Boesgaard, Chief Financial Officer. Dr. Bedu Addo will begin with an overview of the company's recent progress in its clinical development program.
Mr. Boesgaard will review the financial results for 2024 fiscal year. And Dr. Shepard would then join the call to help address questions from covering analysts.
As a reminder, during this call, we will make forward-looking statements which are subject to various risks and uncertainties that could cause our actual results to differ materially from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
